Kogan Lori, Schoenfeld-Tacher Regina, Hellyer Peter, Rishniw Mark
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Science, Colorado State University, Fort Collins, CO, United States.
Department of Molecular and Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States.
Front Vet Sci. 2019 Jan 10;5:338. doi: 10.3389/fvets.2018.00338. eCollection 2018.
Due to the myriad of laws concerning cannabis, there is little empirical research regarding the veterinary use of cannabidiol (CBD). This study used the Veterinary Information Network (VIN) to gauge US veterinarians' knowledge level, views and experiences related to the use of in the medical treatment of dogs. Participants ( = 2130) completed an anonymous, online survey. Results were analyzed based on legal status of recreational marijuana in the participants' state of practice, and year of graduation from veterinary school. Participants felt comfortable in their knowledge of the differences between Δ9-tetrahydrocannabinol (THC) and marijuana, as well as the toxic effects of marijuana in dogs. Most veterinarians (61.5%) felt comfortable discussing the use of CBD with their colleagues, but only 45.5% felt comfortable discussing this topic with clients. No differences were found based on state of practice, but recent graduates were less comfortable discussing the topic. Veterinarians and clients in states with legalized recreational marijuana were more likely to talk about the use of CBD products to treat canine ailments than those in other states. Overall, CBD was most frequently discussed as a potential treatment for pain management, anxiety and seizures. Veterinarians practicing in states with legalized recreational marijuana were more likely to advise their clients and recommend the use of CBD, while there was no difference in the likelihood of prescribing CBD products. Recent veterinary graduates were less likely to recommend or prescribe CBD. The most commonly used CBD formulations were oil/extract and edibles. These were most helpful in providing analgesia for chronic and acute pain, relieving anxiety and decreasing seizure frequency/severity. The most commonly reported side-effect was sedation. Participants felt their state veterinary associations and veterinary boards did not provide sufficient guidance for them to practice within applicable laws. Recent graduates and those practicing in states with legalized recreational marijuana were more likely to agree that research regarding the use of CBD in dogs is needed. These same groups also felt that marijuana and CBD should not remain classified as Schedule I drugs. Most participants agreed that both marijuana and CBD products offer benefits for humans and expressed support for use of CBD products for animals.
由于涉及大麻的法律繁多,关于大麻二酚(CBD)在兽医领域应用的实证研究很少。本研究利用兽医信息网络(VIN)来评估美国兽医关于在犬类医疗中使用CBD的知识水平、观点和经验。参与者(n = 2130)完成了一项匿名在线调查。根据参与者执业所在州的娱乐用大麻法律地位以及兽医学院毕业年份对结果进行分析。参与者对了解Δ9 - 四氢大麻酚(THC)和大麻之间的差异以及大麻对犬类的毒性作用感到安心。大多数兽医(61.5%)对与同事讨论CBD的使用感到安心,但只有45.5%对与客户讨论该话题感到安心。根据执业所在州未发现差异,但刚毕业的兽医对讨论该话题不太安心。与其他州相比,娱乐用大麻合法化州的兽医和客户更有可能谈论使用CBD产品治疗犬类疾病。总体而言,CBD最常被讨论作为疼痛管理、焦虑和癫痫发作的潜在治疗方法。在娱乐用大麻合法化州执业的兽医更有可能建议客户并推荐使用CBD,而在开具CBD产品的可能性方面没有差异。刚毕业的兽医毕业生不太可能推荐或开具CBD。最常用的CBD制剂是油/提取物和可食用产品。这些在为慢性和急性疼痛提供镇痛、缓解焦虑以及降低癫痫发作频率/严重程度方面最有帮助。最常报告的副作用是镇静。参与者认为他们所在州的兽医协会和兽医委员会没有为他们在适用法律范围内执业提供足够的指导。刚毕业的兽医和在娱乐用大麻合法化州执业的兽医更有可能同意需要对犬类使用CBD进行研究。这些相同的群体还认为大麻和CBD不应再被列为一类药物。大多数参与者同意大麻和CBD产品对人类都有好处,并表示支持将CBD产品用于动物。